HCC827Homo sapiens (Human)Cancer cell line
Also known as: Hamon Cancer Center 827, HCC0827, HCC 827, HCC-827
Quick Overview
Human lung cancer cell line with EGFR mutations, used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_2063 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
| Age | 39 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | Lung adenocarcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenocarcinoma |
| OncoTree Code | LUAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000012_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Val218del (c.646_648GTG[2]) (c.652_654delGTG) | Homozygous | - | PubMed=31541927 |
| MutationSimple | EGFR | p.Glu746_Ala750del (c.2236_2250del15) | Unspecified | - | PubMed=16105816 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Potential utility of a 4th-generation EGFR-TKI and exploration of resistance mechanisms -- an in vitro study.
Mitsudomi T., Tsutani Y.
Biomedicines 12:1412.1-1412.13(2024).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Proteomic and ultrastructural analysis of Clara cell and type II alveolar epithelial cell-type lung cancer cells.
Hou W.-L., Chang M., Liu X.-F., Hu L.-S., Hua S.-C.
Transl. Cancer Res. 9:565-576(2020).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.
Minna J.D., Wistuba I.I., Pertsemlidis A.
Oncotarget 9:29601-29618(2018).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Comparative proteome analysis across non-small cell lung cancer cell lines.
Daub H.
J. Proteomics 130:1-10(2016).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.
Genome Res. 23:1434-1445(2013).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Halmos B., Bivona T.G.
Nat. Genet. 44:852-860(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Lung cancer cell lines as tools for biomedical discovery and research.
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
J. Natl. Cancer Inst. 102:1310-1321(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Cell 131:1190-1203(2007).
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.
Gazdar A.F., Lam S., MacAulay C., Lam W.L.
Int. J. Cancer 118:1556-1564(2006).
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Minna J.D.
Oncogene 20:1005-1009(2001).
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.
Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.
Cancer Res. 60:4894-4906(2000).